{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2017)
Source URL:
First approved in 2017
Source:
21 CFR 352
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
M020
(2023)
Source URL:
First approved in 2017
Source:
21 CFR 352
Source URL:
Class:
POLYMER
Status:
US Approved Rx
(2017)
First approved in 2017
Class:
STRUCTURALLY DIVERSE
Status:
US Approved Rx
(2017)
First approved in 2017
Class:
STRUCTURALLY DIVERSE
Status:
US Approved Rx
(2017)
First approved in 2017
Class:
STRUCTURALLY DIVERSE
Status:
US Approved Allergenic Extract
(2017)
Source:
BLA125592
(2017)
Source URL:
First approved in 2017
Source:
BLA125592
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 333A
(2022)
Source URL:
First approved in 2017
Source:
21 CFR 347
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
ANDA075357
(2023)
Source URL:
First approved in 2017
Source:
Thera Derm by Manna Omni International Incorporated
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 348
(2019)
Source URL:
First approved in 2017
Source:
21 CFR 347
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 333D
(2017)
Source URL:
First approved in 2017
Source:
21 CFR 333D
Source URL:
Class:
STRUCTURALLY DIVERSE
